In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results < Back to Main

Page Options

  • Print This Page
  • Email This Document

Search Trial Results

Related Pages

Non-Hodgkin Lymphoma Trial Results

Study Suggests New Treatment Option for Some Lymphomas
(Posted: 06/13/2012) - Updated findings from a large European clinical trial indicate that patients with some types of lymphoma could initially be treated with the chemotherapy drug bendamustine (Treanda) and the targeted agent rituximab (Rituxan).

Romidepsin Reduces Disease Burden and Skin Symptoms in Patients with Previously Treated Cutaneous T-Cell Lymphoma
(Posted: 11/08/2010) - Clinical trial results published October 10, 2010, in The Journal of Clinical Oncology, show that romidepsin (Istodax®), a type of targeted therapy called a histone deacetylase inhibitor, reduced the symptoms and tumor burden of cutaneous T-cell lymphoma in many patients with advanced disease.

Drug Slows Progression of Cutaneous T-Cell Lymphoma
(Posted: 03/31/2010) - Patients with cutaneous T-cell lymphoma who received the drug denileukin diftitox survived without disease progression for a median of more than 2 years, compared with just over 4 months for patients who received a placebo, according to a study published March 8, 2010, in the Journal of Clinical Oncology.

Trial Suggests New First-line Treatment Option for Slow-growing Lymphomas
(Posted: 12/28/2009) - Results from a phase III clinical trial conducted in Germany suggest that the standard initial treatment for patients with slow developing (or indolent) types of B-cell lymphoma should be changed.

Maintenance Rituximab May Improve Survival in Follicular Lymphoma
(Posted: 04/02/2009) - Follicular lymphoma patients who receive maintenance therapy with rituximab after their disease goes into remission may have better survival than those who do not receive such therapy, according to the February 18, 2009, issue of Journal of the National Cancer Institute.

1 2  Next >